Pharmacogenomics News and Research

RSS

The terms pharmacogenomics and pharmacogenetics are often used interchangeably to describe a field of research focused on how genes affect individual responses to medicines. Whether a medicine works well for you—or whether it causes serious side effects—depends, to a certain extent, on your genes.

Genetic discovery could take guesswork out of prescribing correct dose of drugs

The discovery of genetic differences affecting up to a third of the population could take the guesswork out of prescribing the correct dose of 25 percent of drugs currently on the market, researchers say.

2 Oct 2013

Mayo Clinic to host annual Individualizing Medicine Conference from Sept. 30 to Oct. 2

From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice.

18 Sep 2013

Gentris expands genomic biomarker offering with launch of Affymetrix GeneChip HTA services

Gentris Corporation, a global leader in pharmacogenomics and biorepository solutions, announced today that it is expanding its genomic biomarker offering with the launch of Affymetrix GeneChip Human Transcriptome Array services.

17 Sep 2013

UCSF to receive grant to study gene sequencing aimed at detecting disorders in newborns

UC San Francisco will receive $4.5 million over the next five years for a pilot project to assess whether large-scale gene sequencing aimed at detecting disorders and conditions can and should become a routine part of newborn testing.

6 Sep 2013

Research into 'personalised' medicine is being led by Greenwich team

Research into 'personalised' medicine is being led by a University of Greenwich team. Currently, many medicines which are prescribed to patients either do not work properly or have some significant side effects. The aim of personalised medicine, sometimes called 'precision' medicine, is to ensure that the most appropriate medicine is given to each patient and that the medicine is both effective and safe.

5 Sep 2013

Vanderbilt adds genetic screening for drug tacrolimus to PREDICT program

Vanderbilt has added genetic screening for the drug tacrolimus to its personalize medicine pharmacogenomics program PREDICT. The new drug screening protocol was added following data that shows a single genetic variation largely impacts different dose requirements for patients.

27 Aug 2013

Genetic variations in genes could put patients at risk for statin-associated muscle injury: Study

Statins, a class of drugs used to lower cholesterol, are among the best selling drugs in North America and around the world. However, statin myopathy, which results in muscle pain and weakness, is a common side effect affecting up to 10 percent of statin users. A recent study led by Dr. Richard Kim of the Lawson Health Research Institute, in collaboration with Dr. Robert Hegele of Robarts Research Institute, and researchers from Vanderbilt University, found that commonly occurring genetic variations in a person's genes could put them at risk for statin-associated muscle injury.

7 Aug 2013

HistoGenetics selects MiSeq sequencing system from Illumina for use in CLIA laboratory

Illumina, Inc. today announced that HistoGenetics, the leader in high-resolution sequence-based human leukocyte antigen testing services, has selected the MiSeq sequencing system for use in its CLIA laboratory.

From Illumina, Inc. 22 Jul 2013

Scientists develop statistical models to predict which drug is best for specific disease

Medicines that are personally tailored to your DNA are becoming a reality, thanks to the work of U.S. and Chinese scientists who developed statistical models to predict which drug is best for a specific individual with a specific disease.

17 Jul 2013

Assurex Health announces release of new psychiatric pharmacogenomic test panel

Assurex Health today announced the release of GeneSight Psychotropic 2.0, its lead psychiatric pharmacogenomic test panel. This latest GeneSight Psychotropic version has been updated to include four additional medications that now cover a total of 36 of the most commonly prescribed psychotropic medications in the US.

15 Jul 2013

ELSIP: Integrating personalized medicine into clinical practice

Lynn G. Dressler Dr. P.H. Director, Personalized Medicine and Pharmacogenomics, Mission Health, Fullerton Genetics Center will present: Addressing the Ethical, Legal, Social and Policy Issues Related to Integrating Personalized Medicine into Routine Clinical Care at the 5th Annual Personalized Medicine Conference in Boston, MA on October 21- 22, 2013.

11 Jul 2013

Fondation Leducq grants $6M to cardiovascular scientists to help advance cardiac regeneration therapeutics

The Fondation Leducq in Paris, France, dedicated to improving human health through international efforts to combat cardiovascular disease, awarded a $6 million grant award to a new global research network of cardiovascular scientists which includes three researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai.

2 Jul 2013

Gene variants may predict which women are most likely to benefit from breast cancer therapy

In women at high risk for breast cancer, a long-term drug treatment can cut the risk of developing the disease in half. Researchers supported by the National Institutes of Health have now identified two gene variants that may predict which women are most likely to benefit from this therapy—and which should avoid it.

14 Jun 2013

Genetic variations may help predict breast cancer risk in women who receive preventive therapy

Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery.

14 Jun 2013

Study: New genetic marker predicts warfarin dose in African-Americans

A newfound genetic marker promises to better predict warfarin dose in African-Americans, according to a study published online today in The Lancet. If confirmed in further studies, the finding may help to avert more of the bleeds and blood clots that come when a patient's starting dose misses the drug's narrow safety window.

5 Jun 2013

Mayo Clinic researchers complete world's first whole exome sequence of small intestine carcinoids

Researchers at Mayo Clinic have completed the world's first whole exome sequence of small intestine neuroendocrine tumors, also known to patients and physicians as carcinoids, the most common cancer of the small bowel and one that responds poorly to chemotherapy.

16 May 2013

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.

9 May 2013

Long winter months impact tamoxifen treatment for breast cancer

For women diagnosed with a form of breast cancer known as estrogen receptor positive (ER+) breast cancer, tamoxifen is an essential drug used in the treatment and prevention of recurring breast cancer.

19 Apr 2013

Personalis announces availability of Genome Services for Research

Personalis, Inc. today announced availability of its Genome Services for Research, focusing on accuracy in sequencing, analysis, and interpretation of human genomes. Personalis believes that accuracy is crucial in medicine, both in research and ultimately in clinical use.

14 Feb 2013

Eurofins MWG Operon acquires Illumina HiSeq 2500 and MiSeq sequencers

Eurofins MWG Operon, one of the pioneers and key providers of next generation sequencing (NGS), has added an Illumina HiSeq 2500 and an Illumina MiSeq sequencer to its fleet of NGS sequencers.

From Illumina, Inc. 5 Sep 2012